Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

A study of the dosage and duration for levobupivacaine infusion by the caudal-epidural route in infants aged 3-6 months.

Vashisht R, Bendon AA, Okonkwo I, Patel D, Fullwood C, Ogungbenro K, Aarons L, Darwich AS.

Paediatr Anaesth. 2018 Nov 17. doi: 10.1111/pan.13548. [Epub ahead of print]

PMID:
30447167
2.

Comprehensive Evaluation of the Utility of 20 Endogenous Molecules as Biomarkers of OATP1B Inhibition Compared with Rosuvastatin and Coproporphyrin I.

Barnett S, Ogungbenro K, Ménochet K, Shen H, Humphreys WG, Galetin A.

J Pharmacol Exp Ther. 2019 Jan;368(1):125-135. doi: 10.1124/jpet.118.253062. Epub 2018 Oct 12.

PMID:
30314992
3.

Comparison of piperacillin exposure in the lungs of critically ill patients and healthy volunteers.

Felton TW, Ogungbenro K, Boselli E, Hope WW, Rodvold KA.

J Antimicrob Chemother. 2018 May 1;73(5):1340-1347. doi: 10.1093/jac/dkx541.

PMID:
29385448
4.

Gaining Mechanistic Insight Into Coproporphyrin I as Endogenous Biomarker for OATP1B-Mediated Drug-Drug Interactions Using Population Pharmacokinetic Modeling and Simulation.

Barnett S, Ogungbenro K, Ménochet K, Shen H, Lai Y, Humphreys WG, Galetin A.

Clin Pharmacol Ther. 2018 Sep;104(3):564-574. doi: 10.1002/cpt.983. Epub 2018 Jan 17.

5.

Dose Rationalization of Pembrolizumab and Nivolumab Using Pharmacokinetic Modeling and Simulation and Cost Analysis.

Ogungbenro K, Patel A, Duncombe R, Nuttall R, Clark J, Lorigan P.

Clin Pharmacol Ther. 2018 Apr;103(4):582-590. doi: 10.1002/cpt.875. Epub 2017 Oct 16.

PMID:
28913853
6.

Advanced Methods for Dose and Regimen Finding During Drug Development: Summary of the EMA/EFPIA Workshop on Dose Finding (London 4-5 December 2014).

Musuamba FT, Manolis E, Holford N, Cheung S, Friberg LE, Ogungbenro K, Posch M, Yates J, Berry S, Thomas N, Corriol-Rohou S, Bornkamp B, Bretz F, Hooker AC, Van der Graaf PH, Standing JF, Hay J, Cole S, Gigante V, Karlsson K, Dumortier T, Benda N, Serone F, Das S, Brochot A, Ehmann F, Hemmings R, Rusten IS.

CPT Pharmacometrics Syst Pharmacol. 2017 Jul;6(7):418-429. doi: 10.1002/psp4.12196. Epub 2017 Jul 19.

7.

Choosing an optimal input for an intravenous glucose tolerance test to aid parameter identification.

Martin EC, Yates JWT, Ogungbenro K, Aarons L.

J Pharm Pharmacol. 2017 Oct;69(10):1275-1283. doi: 10.1111/jphp.12759. Epub 2017 Jun 27.

PMID:
28653461
8.

Population Pharmacokinetics of Imatinib in Nigerians With Chronic Myeloid Leukemia: Clinical Implications for Dosing and Resistance.

Adeagbo BA, Olugbade TA, Durosinmi MA, Bolarinwa RA, Ogungbenro K, Bolaji OO.

J Clin Pharmacol. 2017 Dec;57(12):1554-1563. doi: 10.1002/jcph.953. Epub 2017 Jun 15.

PMID:
28618035
9.

The effect of veno-venous ECMO on the pharmacokinetics of Ritonavir, Darunavir, Tenofovir and Lamivudine.

Ghazi Suliman MA, Ogungbenro K, Kosmidis C, Ashworth A, Barker J, Szabo-Barnes A, Davies A, Feddy L, Fedor I, Hayes T, Stirling S, Malagon I.

J Crit Care. 2017 Aug;40:113-118. doi: 10.1016/j.jcrc.2017.03.010. Epub 2017 Mar 12.

PMID:
28384599
10.

Reduction of inflammation after administration of interleukin-1 receptor antagonist following aneurysmal subarachnoid hemorrhage: results of the Subcutaneous Interleukin-1Ra in SAH (SCIL-SAH) study.

Galea J, Ogungbenro K, Hulme S, Patel H, Scarth S, Hoadley M, Illingworth K, McMahon CJ, Tzerakis N, King AT, Vail A, Hopkins SJ, Rothwell N, Tyrrell P.

J Neurosurg. 2018 Feb;128(2):515-523. doi: 10.3171/2016.9.JNS16615. Epub 2017 Feb 24.

PMID:
28298024
11.

Why has model-informed precision dosing not yet become common clinical reality? lessons from the past and a roadmap for the future.

Darwich AS, Ogungbenro K, Vinks AA, Powell JR, Reny JL, Marsousi N, Daali Y, Fairman D, Cook J, Lesko LJ, McCune JS, Knibbe C, de Wildt SN, Leeder JS, Neely M, Zuppa AF, Vicini P, Aarons L, Johnson TN, Boiani J, Rostami-Hodjegan A.

Clin Pharmacol Ther. 2017 May;101(5):646-656. doi: 10.1002/cpt.659. Epub 2017 Apr 4. Review.

PMID:
28182269
12.

Mathematical model of T-cell lymphoblastic lymphoma: disease, treatment, cure or relapse of a virtual cohort of patients.

Eymard N, Volpert V, Kurbatova P, Volpert V, Bessonov N, Ogungbenro K, Aarons L, Janiaud P, Nony P, Bajard A, Chabaud S, Bertrand Y, Kassaï B, Cornu C, Nony P; CRESim project group.

Math Med Biol. 2018 Mar 14;35(1):25-47. doi: 10.1093/imammb/dqw019.

PMID:
28082512
13.

Capsaicin-evoked cough responses in asthmatic patients: Evidence for airway neuronal dysfunction.

Satia I, Tsamandouras N, Holt K, Badri H, Woodhead M, Ogungbenro K, Felton TW, O'Byrne PM, Fowler SJ, Smith JA.

J Allergy Clin Immunol. 2017 Mar;139(3):771-779.e10. doi: 10.1016/j.jaci.2016.04.045. Epub 2016 Jun 15.

14.

Predicting survival of pancreatic cancer patients treated with gemcitabine using longitudinal tumour size data.

Wendling T, Mistry H, Ogungbenro K, Aarons L.

Cancer Chemother Pharmacol. 2016 May;77(5):927-38. doi: 10.1007/s00280-016-2994-x. Epub 2016 Mar 3.

15.

Reduction of a Whole-Body Physiologically Based Pharmacokinetic Model to Stabilise the Bayesian Analysis of Clinical Data.

Wendling T, Tsamandouras N, Dumitras S, Pigeolet E, Ogungbenro K, Aarons L.

AAPS J. 2016 Jan;18(1):196-209. doi: 10.1208/s12248-015-9840-7. Epub 2015 Nov 4.

16.

Study design and population pharmacokinetic analysis of a phase II dose-ranging study of interleukin-1 receptor antagonist.

Ogungbenro K, Hulme S, Rothwell N, Hopkins S, Tyrrell P, Galea J.

J Pharmacokinet Pharmacodyn. 2016 Feb;43(1):1-12.

PMID:
26476629
17.

Application of a Bayesian approach to physiological modelling of mavoglurant population pharmacokinetics.

Wendling T, Dumitras S, Ogungbenro K, Aarons L.

J Pharmacokinet Pharmacodyn. 2015 Dec;42(6):639-57. doi: 10.1007/s10928-015-9430-4. Epub 2015 Aug 1.

PMID:
26231433
18.

Physiologically based pharmacokinetic model for 6-mercpatopurine: exploring the role of genetic polymorphism in TPMT enzyme activity.

Ogungbenro K, Aarons L; CRESim & Epi-CRESim Project Groups.

Br J Clin Pharmacol. 2015 Jul;80(1):86-100. doi: 10.1111/bcp.12588. Epub 2015 Jun 1.

19.

Model-based evaluation of the impact of formulation and food intake on the complex oral absorption of mavoglurant in healthy subjects.

Wendling T, Ogungbenro K, Pigeolet E, Dumitras S, Woessner R, Aarons L.

Pharm Res. 2015 May;32(5):1764-78. doi: 10.1007/s11095-014-1574-1. Epub 2014 Nov 26.

PMID:
25425054
20.

Empirical and semi-mechanistic modelling of double-peaked pharmacokinetic profile phenomenon due to gastric emptying.

Ogungbenro K, Pertinez H, Aarons L.

AAPS J. 2015 Jan;17(1):227-36. doi: 10.1208/s12248-014-9693-5. Epub 2014 Nov 21.

21.

A physiologically based pharmacokinetic model for clobazam and stiripentol in adults and children.

Ogungbenro K, Aarons L; CRESim & Epi-CRESim Project Groups.

Pharm Res. 2015 Jan;32(1):144-57. doi: 10.1007/s11095-014-1451-y. Epub 2014 Jul 23.

PMID:
25052507
22.

A physiologically based pharmacokinetic model for Valproic acid in adults and children.

Ogungbenro K, Aarons L; CRESim & Epi-CRESim Project Groups.

Eur J Pharm Sci. 2014 Oct 15;63:45-52. doi: 10.1016/j.ejps.2014.06.023. Epub 2014 Jul 7.

PMID:
25010262
23.

Physiologically based pharmacokinetic modelling of methotrexate and 6-mercaptopurine in adults and children. Part 2: 6-mercaptopurine and its interaction with methotrexate.

Ogungbenro K, Aarons L; CRESim & Epi-CRESim Project Groups.

J Pharmacokinet Pharmacodyn. 2014 Apr;41(2):173-85. doi: 10.1007/s10928-014-9355-3. Epub 2014 Mar 21.

PMID:
24651962
24.

Physiologically based pharmacokinetic modelling of methotrexate and 6-mercaptopurine in adults and children. Part 1: methotrexate.

Ogungbenro K, Aarons L; CRESim & Epi-CRESim Project Groups.

J Pharmacokinet Pharmacodyn. 2014 Apr;41(2):159-71. doi: 10.1007/s10928-014-9354-4. Epub 2014 Mar 21.

PMID:
24651961
25.

Methods and software tools for design evaluation in population pharmacokinetics-pharmacodynamics studies.

Nyberg J, Bazzoli C, Ogungbenro K, Aliev A, Leonov S, Duffull S, Hooker AC, Mentré F.

Br J Clin Pharmacol. 2015 Jan;79(1):6-17. doi: 10.1111/bcp.12352.

26.

Precision criteria to derive sample size when designing pediatric pharmacokinetic studies: which measure of variability should be used?

Salem F, Ogungbenro K, Vajjah P, Johnson TN, Aarons L, Rostami-Hodjegan A.

J Clin Pharmacol. 2014 Mar;54(3):311-7. doi: 10.1002/jcph.206. Epub 2013 Nov 19.

PMID:
24122884
27.

Experimental designs for small randomised clinical trials: an algorithm for choice.

Cornu C, Kassai B, Fisch R, Chiron C, Alberti C, Guerrini R, Rosati A, Pons G, Tiddens H, Chabaud S, Caudri D, Ballot C, Kurbatova P, Castellan AC, Bajard A, Nony P; CRESim & Epi-CRESim Project Groups, Aarons L, Bajard A, Ballot C, Bertrand Y, Bretz F, Caudri D, Castellan C, Chabaud S, Cornu C, Dufour F, Dunger-Baldauf C, Dupont JM, Fisch R, Guerrini R, Jullien V, Kassaï B, Nony P, Ogungbenro K, Pérol D, Pons G, Tiddens H, Rosati A, Alberti C, Chiron C, Kurbatova P, Nabbout R.

Orphanet J Rare Dis. 2013 Mar 25;8:48. doi: 10.1186/1750-1172-8-48. Review.

28.

A semi-mechanistic gastric emptying pharmacokinetic model for (13)C-octanoic acid: an evaluation using simulation.

Ogungbenro K, Aarons L.

Eur J Pharm Sci. 2012 Feb 14;45(3):302-10. doi: 10.1016/j.ejps.2011.11.020. Epub 2011 Dec 3.

PMID:
22155547
29.

The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors.

Lane S, Al-Zubiedi S, Hatch E, Matthews I, Jorgensen AL, Deloukas P, Daly AK, Park BK, Aarons L, Ogungbenro K, Kamali F, Hughes D, Pirmohamed M.

Br J Clin Pharmacol. 2012 Jan;73(1):66-76. doi: 10.1111/j.1365-2125.2011.04051.x.

30.

Population Fisher information matrix and optimal design of discrete data responses in population pharmacodynamic experiments.

Ogungbenro K, Aarons L.

J Pharmacokinet Pharmacodyn. 2011 Aug;38(4):449-69. doi: 10.1007/s10928-011-9203-7. Epub 2011 Jun 10.

PMID:
21660504
31.

Translational pharmacokinetics: challenges of an emerging approach to drug development in stroke.

Greenhalgh AD, Ogungbenro K, Rothwell NJ, Galea JP.

Expert Opin Drug Metab Toxicol. 2011 Jun;7(6):681-95. doi: 10.1517/17425255.2011.570259. Epub 2011 Apr 27. Review.

PMID:
21521135
32.

Structural identifiability analysis of pharmacokinetic models using DAISY: semi-mechanistic gastric emptying models for 13C-octanoic acid.

Ogungbenro K, Aarons L.

J Pharmacokinet Pharmacodyn. 2011 Apr;38(2):279-92. doi: 10.1007/s10928-011-9193-5. Epub 2011 Feb 24.

PMID:
21347679
33.

A semi-mechanistic gastric emptying model for the population pharmacokinetic analysis of orally administered acetaminophen in critically ill patients.

Ogungbenro K, Vasist L, Maclaren R, Dukes G, Young M, Aarons L.

Pharm Res. 2011 Feb;28(2):394-404. doi: 10.1007/s11095-010-0290-8. Epub 2010 Oct 15.

PMID:
20949310
34.

Sample size/power calculations for population pharmacodynamic experiments involving repeated-count measurements.

Ogungbenro K, Aarons L.

J Biopharm Stat. 2010 Sep;20(5):1026-42. doi: 10.1080/10543401003619205.

PMID:
20721789
35.

Intravenous anakinra can achieve experimentally effective concentrations in the central nervous system within a therapeutic time window: results of a dose-ranging study.

Galea J, Ogungbenro K, Hulme S, Greenhalgh A, Aarons L, Scarth S, Hutchinson P, Grainger S, King A, Hopkins SJ, Rothwell N, Tyrrell P.

J Cereb Blood Flow Metab. 2011 Feb;31(2):439-47. doi: 10.1038/jcbfm.2010.103. Epub 2010 Jul 14.

36.

Optimal design of pharmacokinetic studies.

Aarons L, Ogungbenro K.

Basic Clin Pharmacol Toxicol. 2010 Mar;106(3):250-5. doi: 10.1111/j.1742-7843.2009.00533.x. Epub 2010 Jan 20. Review.

37.

Sample size/power calculations for repeated ordinal measurements in population pharmacodynamic experiments.

Ogungbenro K, Aarons L.

J Pharmacokinet Pharmacodyn. 2010 Feb;37(1):67-83. doi: 10.1007/s10928-009-9144-6. Epub 2009 Dec 5.

PMID:
19967433
38.

Population pharmacokinetics and optimal design of paediatric studies for famciclovir.

Ogungbenro K, Matthews I, Looby M, Kaiser G, Graham G, Aarons L.

Br J Clin Pharmacol. 2009 Oct;68(4):546-60. doi: 10.1111/j.1365-2125.2009.03479.x.

39.

Sample-size calculations for multi-group comparison in population pharmacokinetic experiments.

Ogungbenro K, Aarons L.

Pharm Stat. 2010 Oct-Dec;9(4):255-68. doi: 10.1002/pst.388.

PMID:
19714737
40.

Drug-drug interaction predictions with PBPK models and optimal multiresponse sampling time designs: application to midazolam and a phase I compound. Part 1: comparison of uniresponse and multiresponse designs using PopDes.

Chenel M, Bouzom F, Aarons L, Ogungbenro K.

J Pharmacokinet Pharmacodyn. 2008 Dec;35(6):635-59. doi: 10.1007/s10928-008-9104-6. Epub 2009 Jan 7.

PMID:
19130188
41.

Drug-drug interaction predictions with PBPK models and optimal multiresponse sampling time designs: application to midazolam and a phase I compound. Part 2: clinical trial results.

Chenel M, Bouzom F, Cazade F, Ogungbenro K, Aarons L, Mentré F.

J Pharmacokinet Pharmacodyn. 2008 Dec;35(6):661-81. doi: 10.1007/s10928-008-9105-5. Epub 2009 Jan 7.

42.

An effective approach for obtaining optimal sampling windows for population pharmacokinetic experiments.

Ogungbenro K, Aarons L.

J Biopharm Stat. 2009;19(1):174-89. doi: 10.1080/10543400802536131.

PMID:
19127474
43.

Application of optimal design methodologies in clinical pharmacology experiments.

Ogungbenro K, Dokoumetzidis A, Aarons L.

Pharm Stat. 2009 Jul-Sep;8(3):239-52. doi: 10.1002/pst.354. Review.

PMID:
19009585
44.

Sample size calculations for population pharmacodynamic experiments involving repeated dichotomous observations.

Ogungbenro K, Aarons L.

J Biopharm Stat. 2008;18(6):1212-27. doi: 10.1080/10543400802375845.

PMID:
18991118
45.

Optimisation of sampling windows design for population pharmacokinetic experiments.

Ogungbenro K, Aarons L.

J Pharmacokinet Pharmacodyn. 2008 Aug;35(4):465-82. doi: 10.1007/s10928-008-9097-1. Epub 2008 Sep 9.

PMID:
18780163
46.

How many subjects are necessary for population pharmacokinetic experiments? Confidence interval approach.

Ogungbenro K, Aarons L.

Eur J Clin Pharmacol. 2008 Jul;64(7):705-13. doi: 10.1007/s00228-008-0493-7. Epub 2008 May 16.

PMID:
18483725
47.

Incorporating correlation in interindividual variability for the optimal design of multiresponse pharmacokinetic experiments.

Ogungbenro K, Graham G, Gueorguieva I, Aarons L.

J Biopharm Stat. 2008;18(2):342-58. doi: 10.1080/10543400701697208.

PMID:
18327725
48.

Design of population pharmacokinetic experiments using prior information.

Ogungbenro K, Aarons L.

Xenobiotica. 2007 Oct-Nov;37(10-11):1311-30. Review.

PMID:
17968747
49.

A program for individual and population optimal design for univariate and multivariate response pharmacokinetic-pharmacodynamic models.

Gueorguieva I, Ogungbenro K, Graham G, Glatt S, Aarons L.

Comput Methods Programs Biomed. 2007 Apr;86(1):51-61. Epub 2007 Feb 9.

PMID:
17292995
50.

Optimal design for multiresponse pharmacokinetic-pharmacodynamic models - dealing with unbalanced designs.

Ogungbenro K, Gueorguieva I, Majid O, Graham G, Aarons L.

J Pharmacokinet Pharmacodyn. 2007 Jun;34(3):313-31. Epub 2007 Feb 7.

PMID:
17285361

Supplemental Content

Loading ...
Support Center